Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial. The stock was up 15% to $2.50 after the market close on Wednesday.
TC Biopharm (Holdings) plc intends to begin proof-of-concept preclinical studies for its lead therapeutic TCB-008, to treat H5N1, or bird flu. TCB-008 is an allogeneic, unmodified cell therapy ...